Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Zentalis Pharmaceuticals, Inc. (ZNTL : NSDQ)

• Company Description    Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics targeting cancers. The company's lead programs consist of ZN-c5, an oral selective estrogen receptor degrader for estrogen-receptor-positive, HER2-negative breast cancer which is in clinical stage. It operates principally in New York and San Diego. Zentalis Pharmaceuticals, Inc. is based in NEW YORK. Number of Employees: 166

• Price / Volume Information    Yesterday's Closing Price: $1.37 Daily Weekly Monthly 20 Day Moving Average: 1,359,229 shares Shares Outstanding: 71.95 (millions) Market Capitalization: $98.57 (millions) Beta: 1.59 52 Week High: $5.44 52 Week Low: $1.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.16% -9.68% 12 Week 6.20% -10.67% Year To Date -54.78% -57.66%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10275 SCIENCE CENTER DRIVE SUITE 200 - SAN DIEGO,CA 92121 USA ph: 858-263-4333 fax: - ehickin@zentalis.com https://zentalis.com

• General Corporate Information    Officers Julie Eastland - Chief Executive Officer and Director Scott Myers - Chairperson Vincent A. Vultaggio - Senior Vice President; Finance and Principal Accou David Johnson - Director Enoch Kariuki - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 98943L107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/08/25 Share - Related Items Shares Outstanding: 71.95 Most Recent Split Date: (:1) Beta: 1.59 Market Capitalization: $98.57 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.59 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.32 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.33 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -578.57% vs. Previous Quarter: -1.52% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -65.48 12/31/24 - -43.28 ROA 06/30/25 - - 03/31/25 - -51.05 12/31/24 - -34.37 Current Ratio 06/30/25 - - 03/31/25 - 6.94 12/31/24 - 7.32 Quick Ratio 06/30/25 - - 03/31/25 - 6.94 12/31/24 - 7.32 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - -245.74 Book Value 06/30/25 - - 03/31/25 - 4.11 12/31/24 - 4.73 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©